Lurasidone Pharmacokinetics in Chinese Psychiatric Inpatients with Valproate Co-Medication

A population pharmacokinetic model of lurasidone developed from therapeutic drug monitoring data of 156 Chinese psychiatric inpatients providing 212 serum concentrations. The study, authored by Ye Yang and published on figshare in 2026, quantifies the impact of age and valproate co-medication on drug clearance and exposure.

Use Cases

• Modeling drug clearance based on age and concomitant medication covariates.
• Simulating lurasidone concentration profiles for different patient subgroups.
• Informing therapeutic drug monitoring interpretation guidelines for Chinese psychiatric patients.
• Investigating drug-drug interactions between lurasidone and valproate.

Strengths

• Model developed from 212 serum concentration measurements.
• Identifies a 47.7% increase in apparent clearance due to valproate co-administration.
• Data sourced from 156 patients, providing a clinical sample size.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying data is unknown, which may limit suitability assessment.
• The dataset is very small at 15.0 KB, indicating limited scope.

Provenance

Source

Ye Yang via figshare.

Collection Method

Routine therapeutic drug monitoring data analyzed using nonlinear mixed-effects modeling (NONMEM).

Freshness

Last updated 2026-05-12 05:26:58; freshness should be verified.

Geography

Chinese psychiatric inpatients.